Posted inNews and Updates
Modern Clinical Trials: Why Tech and Synergy Matter
Discover how strategic collaborations and digital innovation are transforming clinical trial success rates, speeding up drug development, and boosting RWE.
Posted inNews and Updates
New Strategy to Overcome Drug Resistance in Pancreatic Cancer
Researchers identify key mechanisms of resistance to the RAS inhibitor daraxonrasib, paving the way for new, highly effective combination cancer therapies.
Posted inNews and Updates
New B-Cell Therapy Advances in CNS Autoimmune Trials
Discover how next-gen B-cell depletion therapies are reshaping CNS autoimmune research and setting a new gold standard for regulatory approval processes.
Posted inNews and Updates
TNX-103 Phase 3 Trial Results for PH-HFpEF Revealed
Tenax Therapeutics releases Phase 3 LEVEL trial data for TNX-103 in PH-HFpEF patients. Discover the key clinical outcomes for this potential new therapy.
Posted inNews and Updates
Radspherin Dosimetry Data: Advancing Peritoneal Cancer Care
New dosimetry data for Radspherin offers a breakthrough in treating peritoneal metastases, highlighting the potential of targeted alpha-emitter therapy.
Posted inNews and Updates
Kodiak Sciences Launches Phase 3 ALTO Trial for DME
Kodiak Sciences has started its Phase 3 ALTO trial for KSI-501. Discover how this bispecific drug aims to transform Diabetic Macular Edema treatment.
Posted inNews and Updates
Sionna Therapeutics’ SION-719 Misses Key CF Trial Goal
Sionna Therapeutics reports that its CF drug SION-719 failed to meet primary sweat chloride endpoints in a recent study. Read the latest clinical update here.
Posted inNews and Updates
Haleon & A*STAR Launch Study on Women’s Metabolic Health
Haleon partners with Singapore’s A*STAR to launch a clinical study investigating metabolic health markers, aiming to improve wellness for Asian women.
Posted inNews and Updates
Expanding Cancer Trial Access: New Initiatives Explained
City of Hope is transforming oncology research by decentralizing clinical trials. Discover how their new model improves equitable access to cancer care.
Posted inNews and Updates
Sionna Cystic Fibrosis Drug Trial Fails: Vertex Maintains Lead
Sionna Therapeutics halts its SION-109 CF trial after failing to meet key endpoints, cementing Vertex Pharmaceuticals' lead in the cystic fibrosis market.